Endocrine Abstracts

JOINT1648

Background: The Growzen® Connect digital ecosystem has been developed to support timely treatment optimisation for patients on recombinant human growth hormone (r-hGH) therapy. This ecosystem includes electronic injection devices with adherence data transmitters and a platform for healthcare professionals (HCPs) to monitor real-time patient adherence. This study aimed to investigate whether HCPs’ interaction with this platform influences adherence to r-hGH therapy in patients from Spain.

Methods: Adherence data (optimal [≥85%] vs suboptimal [<85%]) at the patient level and three clinic-level metrics were extracted from the platform between July 2023 and June 2024. Patients from Spain aged <18 years were selected. The first metric for platform engagement was frequency of use, which is the number of clinic connections by number of patients, stratified by ≥1 (at least one connection/patient/year), >0-<1 (less than one connection/patient/year), and 0 (no connection). The second metric for platform engagement was data entry, which is the number of growth data entries by the number of patients, stratified by ≥1 (at least one measurement/patient/year), >0-<1 (less than one measurement/patient/year), and 0 (no measurement). The metric for treatment engagement is defined as the number of dose changes by number of patients, stratified by ≥2 (at least two dose changes/patient/year), ≥1-<2 (less than two and greater or equal to one dose changes/patient/year), and <1 (less than one dose change/patient/year). Multi-level logistic regression analyses were performed with adherence as an outcome and metrics as input adjusted for standardised age at treatment initiation and standardised time on treatment.

Results: Adherence data were obtained from 3,980 patients in 186 clinics. In July 2023, the mean age at treatment initiation was 10.7 years and the mean time on treatment was 21 months as of July 2023, the start of the extraction period. The proportions of patients with optimal adherence were 76% (n = 883/1,161), 79% (n = 1,998/2,542; P = 0.13), and 88% (n = 245/277; P <0.001) in clinics with no (n = 92), >0-<1 (n = 65), and ≥1 (n = 29) connections/patient/year, respectively. The proportions were 78% (n = 2,551/3,270), 80% (n = 542/675; P = 0.86), and 94% (n = 33/35; P = 0.009) in clinics with no (n = 173), >0-<1 (n = 12), and ≥1 (n = 1) measurements/patient/year. Furthermore, the proportions were 71% (161/228), 78% (2,207/2,833; P = 0.62), and 82% (758/919; P = 0.25) in clinics with <1 (n = 27), ≥1-<2 (n = 111), and ≥2 (n = 48) dose changes/patient/year, respectively.

Conclusions: Our research revealed that HCPs’ interaction with the digital adherence monitoring platform Growzen® Connect positively influences patient adherence to r-hGH therapy in Spain.